These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10986307)

  • 1. Prediction of disease progression in early rheumatoid arthritis by ICTP, RF and CRP. A comparative 3-year follow-up study.
    Aman S; Paimela L; Leirisalo-Repo M; Risteli J; Kautiainen H; Helve T; Hakala M
    Rheumatology (Oxford); 2000 Sep; 39(9):1009-13. PubMed ID: 10986307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression.
    Hakala M; Risteli J; Aman S; Kautiainen H; Korpela M; Hannonen P; Leirisalo-Repo M; Laasonen L; Paimela L; Möttönen T;
    Scand J Rheumatol; 2008; 37(2):90-3. PubMed ID: 18415764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I collagen degradation product in serum of patients with early rheumatoid arthritis: relationship to disease activity and radiological progression in a 3-year follow-up.
    Paimela L; Leirisalo-Repo M; Risteli L; Hakala M; Helve T; Risteli J
    Br J Rheumatol; 1994 Nov; 33(11):1012-6. PubMed ID: 7981987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased type I collagen degradation in early rheumatoid arthritis.
    Kotaniemi A; Isomäki H; Hakala M; Risteli L; Risteli J
    J Rheumatol; 1994 Sep; 21(9):1593-6. PubMed ID: 7799334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of synovial fluid analysis in the assessment of knee joint destruction in arthritis in a three year follow up study.
    Aman S; Risteli J; Luukkainen R; Risteli L; Kauppi M; Nieminen P; Hakala M
    Ann Rheum Dis; 1999 Sep; 58(9):559-62. PubMed ID: 10460189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assay for cross-linked carboxyterminal telopeptide of type I collagen (ICTP) unlike CrossLaps assay reflects increased pathological degradation of type I collagen in rheumatoid arthritis.
    Sassi ML; Aman S; Hakala M; Luukkainen R; Risteli J
    Clin Chem Lab Med; 2003 Aug; 41(8):1038-44. PubMed ID: 12964811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis.
    Chang PY; Yang CT; Cheng CH; Yu KH
    Int J Rheum Dis; 2016 Sep; 19(9):880-6. PubMed ID: 25940989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease.
    Valleala H; Laasonen L; Koivula MK; Mandelin J; Friman C; Risteli J; Konttinen YT
    J Rheumatol; 2003 Mar; 30(3):468-73. PubMed ID: 12610803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis.
    Hakala M; Aman S; Luukkainen R; Risteli L; Kauppi M; Nieminen P; Risteli J
    Ann Rheum Dis; 1995 Nov; 54(11):886-90. PubMed ID: 7492237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study.
    Roux-Lombard P; Eberhardt K; Saxne T; Dayer JM; Wollheim FA
    Rheumatology (Oxford); 2001 May; 40(5):544-51. PubMed ID: 11371663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis.
    Manfredsdottir VF; Vikingsdottir T; Jonsson T; Geirsson AJ; Kjartansson O; Heimisdottir M; Sigurdardottir SL; Valdimarsson H; Vikingsson A
    Rheumatology (Oxford); 2006 Jun; 45(6):734-40. PubMed ID: 16403829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis.
    Hakala M; Risteli L; Manelius J; Nieminen P; Risteli J
    Ann Rheum Dis; 1993 Dec; 52(12):866-9. PubMed ID: 8311537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type I collagen degradation does not diminish with RA disease duration.
    Hakala M; Aho K; Aman S; Luukkainen R; Kauppi M; Risteli J
    Ann Rheum Dis; 2001 Apr; 60(4):420-2. PubMed ID: 11247878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of anticyclic citrullinated peptide antibodies and/or rheumatoid factor status and clinical presentation in early arthritis: results from the ESPOIR cohort.
    Mouterde G; Lukas C; Goupille P; Flipo RM; Rincheval N; Daurès JP; Combe B
    J Rheumatol; 2014 Aug; 41(8):1614-22. PubMed ID: 25028372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic laboratory markers of joint damage in rheumatoid arthritis.
    Lindqvist E; Eberhardt K; Bendtzen K; Heinegård D; Saxne T
    Ann Rheum Dis; 2005 Feb; 64(2):196-201. PubMed ID: 15458956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis.
    Maksymowych WP; Naides SJ; Bykerk V; Siminovitch KA; van Schaardenburg D; Boers M; Landewé R; van der Heijde D; Tak PP; Genovese MC; Weinblatt ME; Keystone EC; Zhukov OS; Abolhosn RW; Popov JM; Britsemmer K; van Kuijk AW; Marotta A
    J Rheumatol; 2014 Nov; 41(11):2104-13. PubMed ID: 25128504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis.
    Abdel-Nasser AM; Mahmoud MH; El Mansoury TM; Osman AM
    Scand J Rheumatol; 2008; 37(5):329-36. PubMed ID: 18666028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis.
    Plant MJ; Williams AL; O'Sullivan MM; Lewis PA; Coles EC; Jessop JD
    Arthritis Rheum; 2000 Jul; 43(7):1473-7. PubMed ID: 10902748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-DRB1 genes, rheumatoid factor, and elevated C-reactive protein: independent risk factors of radiographic progression in early rheumatoid arthritis. Berlin Collaborating Rheumatological Study Group.
    Listing J; Rau R; Müller B; Alten R; Gromnica-Ihle E; Hagemann D; Zink A
    J Rheumatol; 2000 Sep; 27(9):2100-9. PubMed ID: 10990219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of serum angiopoietin-1 measurement in the diagnosis of early rheumatoid arthritis.
    Ishikawa A; Okada J; Nishi K; Hirohata S
    Clin Exp Rheumatol; 2011; 29(4):604-8. PubMed ID: 21906428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.